Meg is passionate about driving change by collaborating with physicians, technology leaders and solution innovators to improve health care. She has served in product development and business development leadership roles at the AMA and most recently is responsible for driving the roadmap of initiatives that support the AMA’s digital health and medicine strategy. In addition, she has led partnerships and innovation related initiatives, such as the inaugural AMA Healthier Nation Innovation Challenge, the establishment of the AMA Interaction Studio at MATTER, the AMA Physician Innovation Network that enables entrepreneurs and physicians to collaborate on the development of new solutions, the AMA Digital Health & Telehealth Implementation Playbook series, AMA Digital Health research and The Telehealth Initiative with collaborators. She participates on the Advisory Board for MATTER, MassChallenge HealthTech, HealthTech Arkansas, Together.Health and as a TEDMed Research Scholar. She also participates on the Editorial Review Board of The Telehealth and Medicine Today Journal.

Meg has spoken at national conferences such as Health 2.0, Connected Health, HLTH, American Telemedicine Association National Conference, AMA State Advocacy Conference and contributes as speaking faculty for Columbia Business School’s Digital Health program curriculum. She has articles published in Health Affairs, Harvard Business Review and Nature Digital Medicine.

Prior to AMA, Meg worked in the Consumer Product & Retail vertical at Capgemini and at SmithBucklin Corporation for various business and health care clients.

Kamal is an industry leader with 15+ years of experience in digital health from a provider perspective, most recently at MassGeneral Brigham, with a background in digital health strategy, product design and clinical research and validation. Kamal has developed and implemented 100+ digital health programs and is widely published in the value digital health can bring to healthcare delivery.

Alyssa Reisner is a Lead Director and Principal at CVS Health Ventures. In her role, she sources, evaluates, and executes investments in innovative health care companies. She has built strategic relationships and executed investments for CVS Health in areas spanning DTx, women’s health, behavioral health, COVID-19 initiatives, and more.

Katie joined AbbVie in May 2021 as a Director of Regulatory Affairs for the newly formed Digital &
Medical Device Team in the Emerging Technology & Combination Product group. In this role, Katie and
her team support internally developed SaMD projects providing regulatory strategy during development
and GRL support prior to global launch. In addition, Katie is the lead Device Regulatory for the ABBV-
RGX-314 partnership between AbbVie and Regen X Bio supporting both key ancillary devices required
for the Subretinal and Suprachoroidal delivery of the biologic.
Prior to joining AbbVie, Katie held a biomedical engineer and lead reviewer position the US FDA Center
for Devices and Radiological Health (CDRH) in the Cardiovascular Device Division (DCD) in the Office of
Device Evaluation (ODE) from 2006 until 2015. In this role she was the lead reviewer for interventional
cardiovascular devices including guidewires, guide catheters, bare metal, drug eluting and bioabsorbable
stents. After completing the Leadership Readiness program in 2015, Katie joined the Office of Orphan
Products Development (OOPD) in the Commissioner’s Office where she led review of the Humanitarian
Use Device (HUD) designations, supported the Pediatric Device Consortium and Orphan Clinical Trials
grants. Her last official role at the Agency took her back to CDRH where she headed the partnership with
the Medical Device Innovation Consortium (MDIC) in the External Partnerships sector and supported
regulatory science project development across multiple initiatives including Digital Health, In Vitro
Diagnostics, Early Feasibility Studies (EFS), Case for Quality and Science of Patient Input.
Katie holds her undergraduate degree from the University of Pittsburgh (cum laude) in Biomedical
Engineering (2004) and her master’s degree from Maquette University and the Medical College of
Wisconsin in Healthcare Technology Management (2005). Katie resides in NW Washington DC with her
husband, Atiq, and twin boys, Isaac and Isaiah.

Alyssa Dietz, Ph.D. is senior director of Precision Care Strategy at Twill (formerly Happify Health). She is a licensed clinical psychologist who made her way to the digital therapeutics industry after working as a professor and practicing psychologist. She provided Cognitive Behavioral Therapy and Motivational Interviewing for the treatment of substance use disorders and health-related behavior change more broadly. Her research lab studied digital intervention and prevention programs and the use of digital tools to increase access to evidence-based care. She was an assistant professor first at Penn State and later Austin College where she trained future psychological scientists and therapists, directed a research lab, and first learned to translate complex topics to digestible information. Later, she joined Pear Therapeutics where she worked as a Medical Science Liaison, and served as a scientific and clinical resource to a range of stakeholders, including physicians, payers, advocacy groups, and others. She is passionate about revolutionizing access to evidence-based care.

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Kate is a Senior Principal in the EMEA Consulting team at IQVIA, currently based in London. She has over 12 years of consulting experience, working with a broad range of pharmaceutical, biotechnology, diagnostic, and digital health clients. Kate has expertise in market access strategy, launch pricing, companion diagnostics and access strategy in digital health. Kate holds a B.A. from Princeton University in Molecular Biology

Aubrey Shick is a Sr. Digital Health Advisor in the Digital Health Center of Excellence (DHCoE) at FDA’s Center for Devices and Radiological Health (CDRH). Aubrey leads efforts related to digital health policy, transparency of AI/ML-enabled devices, and regulatory science for the DHCoE, promoting user-centered considerations in digital health. Before joining the DHCoE in 2021, Aubrey worked in industry leading product strategy, software user experience (UX) architecture, and validation programs for multiple wellness and digital health startups, Intel’s New Devices Group, and Medtronic. Aubrey’s product experience encompasses artificial intelligence (AI), virtual and augmented reality (VR/AR), wearable computing, embedded computing (IoT), and surgical robotics.

Innovator. Scientist. Thought leader. Technologist. Sleep and Circadian Sciences expert. Creator of Precision and Personalized Population Health. Voted top 100 most inspiring Black Scientists in America by Cell Press. I believe in health and wellness for all through disruptive and scalable innovation. Director of The Media and Innovation Lab, The MIL.

Whitney is a Director of Clinical Project Management. She oversees the implementation of multiple
clinical trials at Curebase, including some in digital therapeutics. She has worked in the decentralized
trial space for over 5 years and in clinical research for over 10.

Steve LoSardo is the vice president of Life Science Solutions and consulting at SoftServe. He’s a dynamic leader and visionary with more than 25 years of experience providing information technology solutions to consumers, life science, and healthcare companies. Steve focuses on working with clients to deliver innovative digital solutions based on web, mobile, voice, IoT, big data, AI/ML, and cloud technologies in the pharmaceutical, biotech, and payer spaces.

Jay Ahlman is Vice President of CPT Coding and Reimbursement Policy and Strategy for the American Medical Association (AMA). Jay joined the AMA in 1999 and has held various roles in healthcare strategy, policy and coding during his tenure. Since 2008, Jay has led the AMA group responsible for the maintenance of the Current Procedural Terminology (CPT) code set and is the lead staff to the CPT Editorial Panel for the AMA. During this time Jay has worked with the CPT Editorial Panel to lead many significant changes, including the evolution of CPT Literature Standards and the launch of new CPT coding sections including the Proprietary Laboratory Analyses (PLA) code section. Jay is also the lead staff to the AMA’s Digital Medicine Payment Advisory Group, which is an advisory body made up of 15 industry experts charged with creating solutions to enable the integration of digital healthcare and telehealth solutions into clinical practice. Most recently, Jay has been involved in the revision of the CPT Evaluation and Management coding structure and the addition of Remote Physiologic and Remote Therapeutic Monitoring codes to the CPT code set.

Smit J. Patel, PharmD serves as the Strategic Program Lead at the Digital Medicine Society (DiMe), a 501(c)(3) global non-profit organization dedicated to advancing digital medicine to optimize human health. His work focuses on applied approaches to the safe, effective, ethical, and equitable use of digital technologies to advance its evaluation and implementation in clinical research and care delivery. He is an Advisory Board member for the Brown-Lifespan Center for Digital Health and the Digital Therapeutic Alliance (DTA) and serves on advisory committees for digital health program(s) at the Association of Community Cancer Centers (ACCC), American Pharmacists Association (APhA), and HealthXL. He also serves on the steering committee for the APACMed Digital health reimbursement alliance.

Shaheen Lakhan, MD, PhD, FAAN, is a physician-scientist, biotech executive, and biopharma board
director with over 20 years of experience in healthcare, academia, and industry focusing on
neuroscience research and development. He is board-certified in both neurology and pain medicine,
with clinical training from Cleveland Clinic and Massachusetts General Hospital.
As an expert in patient-empowering clinical development from drugs to devices, Dr. Lakhan is keen
on transforming medicine and democratizing health care through prescription digital therapeutics
(Chief Medical Officer, Click Therapeutics) and novel drug-delivery platforms (Board Director,
SpineThera). He continues to serve patients as a practicing neurologist and pain specialist (Mount
Auburn Hospital, Cambridge Health Alliance) and is professor of neurology and neuroscience
(Western University, Virginia Tech).
Previously, Dr. Lakhan served as faculty of leading institutions (Harvard Medical School, Case
Western Reserve University), founding department chair and curricular dean (California University of
Science and Medicine), institutional review board chair (Arrowhead Regional Medical Center), chief
of pain management (Virginia Tech - Carilion Clinic), and executive/leadership positions in
biopharma (Sage Therapeutics, Zogenix) and biotech (The Learning Corp, Fern Health).
In addition to exemplary clinical service, Dr. Lakhan has an extensive research, education, advocacy,
and philanthropy portfolio. He has over 100 peer-reviewed publications, books, and book chapters.
For founding the Global Neuroscience Initiative Foundation, he was bestowed the Harvard Medical
School Dean’s Community Service Award. He was also conferred the President’s Call to Service
Award for Lifetime Achievement by President George W. Bush and The U.S. Congressional Award
Gold Medal by Senators Nancy Pelosi and Harry Reid. Further, California Governor Brown and
Virginia Governor Northam have appointed him to prestigious boards including the Health
Professions Education Foundation awarding more than $200 million towards closing the health
equity gap. Recognized by his peers, he was inducted as Fellow of the American Academy of
Neurology, the Academy’s highest designation.

Nick is a Principal in the US Consulting team at IQVIA, currently based in San Francisco. He has over 15 years of consulting and technology strategy experience, working with a broad range of healthcare clients. He has expertise in providing digital health and digital transformation solutions to payers, providers, and global healthcare and life sciences firms. Nick holds a B.S. from the Kelley School of Business at Indiana University.

Micaela Brandau is Vice President of Strategy and Corporate Development at AmerisourceBergen (AB), a
Fortune 10 global healthcare company with a foundation in pharmaceutical distribution and solutions. In
her role, Micaela is focused on working alongside teams at AB to develop and launch solutions aimed at
supporting biopharma companies and stakeholders involved in bringing new innovations to market. She
serves on the team leading the development of DTx Connect, a fully integrated ordering, dispensing and
fulfillment platform that aims to facilitate patient access to physician-ordered digital therapeutics and
diagnostics.
Prior to joining AmerisourceBergen in May 2022, Micaela worked at Johnson & Johnson for more than a
decade, most recently as the Global Strategic Marketing lead for Prostate Cancer. She earned an MBA
from the University of North Carolina at Chapel Hill and a BA from Boston College.

Dr. Caplan is a leading cannabis clinician, educator and advocate and board-certified family physician
with years spent advancing cannabis care and research. Founder of CED Clinic Intl & CED Foundation.
Trained at Tufts and BU, conducted studies at the UCLA Brain Mapping Center. Published in The New
England Journal of Medicine.

Laura is the Head of Clinical Innovation at Click Therapeutics, a biotechnology company that
develops and commercializes FDA approved software applications as medical treatments, focusing
on therapeutic strategy, evidence generation and real-world implementation.
Laura has been part of several successful FDA Breakthrough Designations for software as medical
devices and has overseen numerous research projects in CNS and oncology, tapping into the
potential of virtual trials to empower patients. Prior to Click, Laura was leading clinical operations at
Woebot Health and The Learning Corp.
Laura is keen on tackling health disparities by accelerating digital therapeutic development so that
clinically-proven, safe and effective solutions can be universally available to patients and their
providers.

Amir is an established neuroscientist specialized in digital medicine and clinical innovation. His strategic vision is empowered by real-world data that enable the discovery of clinical insights otherwise not possible solely based on conventional health records. Amir has boundless passion for accelerating novel therapies and creating a path for better patient experience. He brings an entrepreneurial zeal to the clinical world through disruptive technology and AI analytics from proof of concepts to scale-up solutions. Prior to pharma , Amir was a professor of Pediatrics and Epidemiology at Harvard Medical School and Harvard School of Public Health and served as a PI on numerous clinical trials with 200+ publications and conference presentations.

Dr. Risa Weisberg has devoted her career to developing and scientifically testing scalable interventions for common behavioral health problems. Her mission is to expand the reach of high-quality, science-based behavioral health treatment. She has over two decades of research, clinical, and leadership experience which she now brings to lead the clinical direction and research strategy of BehaVR at Chief Clinical Officer. Risa has a doctoral degree in Clinical Psychology from the University at Albany. She completed a doctoral internship and postdoctoral fellowship at Brown University. She is a Professor of Psychiatry at the Boston University School of Medicine and an Adjunct Professor of Family Medicine at the Alpert Medical School of Brown University. She is an expert in cognitive-behavioral therapy and acceptance and commitment therapies. As a primary care psychologist, Risa has broad experience in treatment development and implementation for common behavioral health problems including anxiety, depression, chronic pain, substance use disorder, and adaptation to living with other chronic medical difficulties. Her research has been funded by the National Institutes of Health, the Patient Centered Outcomes Research Institute, the Veterans Administration, and numerous foundations. Risa is a member of the Scientific Council of the Anxiety and Depression Association of America and a Fellow and former Board Member of the Association for Behavioral and Cognitive Therapies.

Dr. Andrew Welchman, Executive Vice President for Impact at ieso, is a Neuroscientist, former Professor at the University of Cambridge, and highly published academic. He has extensive speaking experience which includes addressing the House of Lords. He is responsible for ensuring ieso sets, measures and meets its ambitious social and economic impact goals.

ieso is a multi-award winning provider of evidence-based talking therapy for mood and anxiety disorders. Now available to over 20 million people, ieso was one of the first organisations to successfully develop and deploy evidence-based mental telehealthcare at scale. Leveraging real-world clinical data, ieso has pioneered the application of technologies such as deep-learning and natural language processing to improve the quality and cost-effectiveness of mental healthcare delivery.

Recognising the global demand-supply gap in mental healthcare provision, ieso has recently commenced the clinical development of a range of AI-enabled digital assessment and therapeutic solutions that it hopes will complement and extend human care delivery around the world.

Sean Kinsman, DPT serves as the Chief Clinical Officer at RecoveryOne, a leading
digital health innovator dedicated to improving health outcomes for recovery from
musculoskeletal (MSK) injuries of all types and reducing costs. Dr. Kinsman has been
instrumental in driving RecoveryOne’s expansion into clinical care and is the
architect behind their network of clinicians who service patients through their digital
treatment pathways. He is a Board Certified Orthopedic Clinical Specialist.
Prior to joining RecoveryOne, Dr. Kinsman contributed to the world-renowned “MICU
Study” while working in clinical practice at Johns Hopkins Hospital. The study focused
on the early mobilization of medically complicated patients in an intensive care unit
setting. Dr. Kinsman was also a key contributor to Johns Hopkins’ Hemophilia Clinic
and Cystic Fibrosis teams, managing long-term complications in both populations.
Dr. Kinsman’s previous experience also includes serving as part of a multi-
disciplinary team of Stanford physicians where he contributed to the creation of an
innovative, intensive recovery program for patients who developed dependence to
prescription opioids. The program averaged a 76% clinical success rate over six
years.
He previously also served as Clinic Director at Henning and Cole, a group of
outpatient therapy clinics in the Baltimore area. He earned his BS, MA and DPT at
Northeastern University, Boston, MA

Brendan is the Associate Director of Medical Affairs at Click Therapeutics. He
previously held a position in Medical Affairs at Pear Therapeutics. His experience
includes strategy development, publications, and evidence generation in clinical trials
and real-world studies. Brendan is a neuroscientist by training, earning a PhD from the
University of Vermont and serving as a postdoctoral fellow in the Yale Department of
Psychiatry.

Dr. Snipes is the Associate Director of Clinical Science at Click Therapeutics where she
leads a team focused on building efficacious prescription digital therapeutics for indications
including depression, schizophrenia, and migraine. She is a clinician-scientist with

experience advancing high quality, evidence-based psychological interventions in
healthcare, academia, and industry. She is a licensed clinical psychologist with training from
Henry Ford hospital and Kaiser Permanente Northern California in medically complex health
psychology, behavioral medicine, pain management, trauma, and women’s health. Dr.
Snipes also served as faculty of UMass Medical School.

Dave is an eo co-founder and investor. He oversees the end-to-end experience and product platform.
He is a recognized CX, digital product design, and marketing innovator in health, wealth and consumer
products and was the co-founder of two leading CX, marketing, and technology consultancies (BEAM and
Euro RSCG Circle).

Ted is an experienced media and technology professional with over 25 years of experience in product management and content development. Ted has held various executive, editorial and product management roles at AOL Canada, Yahoo!, and 4INFO where he was Vice President of Products. Starting in 2010 Ted began working as an independent consultant for early-stage companies developing data, online video, and television products and was instrumental in starting RevUp.com, an award-winning company based in Northern California that revolutionized political and non-profit fundraising. Ted is currently working as the Vice President of Product at Propeller Health, one of the top digital health companies in the world that are helping bring connected devices to asthma and COPD patients around the world.

Masashi is the Founder & Managing Partner at Kicker Ventures, an early-stage venture capital fund investing in the companies building the future of healthcare. Masashi is a believer in the role of technology transforming healthcare and is working to create a platform for entrepreneurs to maximize impact globally.

Rich is the Chief Commercial Officer at Click Therapeutics, a biotechnology company that develops and
commercializes FDA approved software applications as medical treatments. As Chief Commercial Officer
Rich oversees Market Access & Public Affairs, Marketing, Sales, Commercial Excellence, New Product
Planning and Commercial Partnership Success.
Rich’s background is in pricing, marketing, finance, and market access. Prior to joining Click, Rich held
various commercial roles at the pharmaceutical company Novo Nordisk. Most recently he was a Vice
President in Market Access, leading their Strategy and Innovation Team and their National Account
Team.
Rich believes in the power that digital therapeutics can bring to support patient outcomes and wants to
put his experience to work to put the industry’s and Click’s technology in the hands of as many patients
as possible.

Derk Arts MD, PhD has over fifteen years of experience in medicine, research and technology. He founded Castor to solve the biggest issues in clinical research: a lack of inclusivity, patient focus and impact of data. Castor enables sponsors worldwide to run patient-centric trials on a unified platform, that helps them maximize the impact of research data on patient lives.

Dr. Derk Arts believes the key to achieving lasting change in the industry is through scalability and standardization. Technology to run better trials and maximize the impact of data should be available to all researchers.

Over the past 12 months, Castor provided pro-bono support to over 300 COVID-19 trials, and provided the entire infrastructure for the World Health Organizations’ Solidarity Trials.

Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain, developing innovative technologies to monitor and stimulate the brain to help many patients in need. She was nominated by IESE Business School as one of the most influential entrepreneurs under 40 in Spain in 2010. She received the EU Prize for Women Innovators from the European Commission EC in 2014. In 2015 & 2016, she was named one of the most inspiring women on the Inspiring Fifty list in Europe. Ana continues breaking the barriers of science and technology in an impactful way with Business Ethics.

Soňa is the CEO and co-founder of Mindpax, a company that brings personalized digital care to patients with severe mental illnesses. Mindpax’s DTX for bipolar disorder will be the first product of its kind offered under German DiGA. With a background in finance, Soňa has 7 years of experience with clinical validation of digital health products. She has been cooperating with European and American leading research institutes and opinion leaders. Her ambition is to keep bringing to market meaningful digital solutions that will change mental illness treatment from a guessing game into a data-driven, continuous, targeted care.

Veera is a hands-on technology executive and business leader with a passion to bring positive change through the power of data and AI. He created Constant Therapy, an award-winning mobile app that uses artificial intelligence to help tens of thousands of people living with neurological conditions regain essential life skills.

Veera also successfully built a number of innovative products at other startups, including at a company acquired by Apple that developed the world’s fastest digital signal processor. He began his career as a Lead Engineer at Motorola developing mobile software and hardware products, and later, as Vice President of Engineering at a startup acquired by Motorola, developed software products that are now used worldwide to manage wireless networks. Veera has six technology patents and recently won TiE Boston’s Entrepreneur of the Year Award. He is an expert mentor at MassChallenge HealthTech and Insight Data Sciences, is a Charter Member of TiE Boston, and is a guest lecturer for Entrepreneurship at Questrom School of Business. Veera holds a PhD in electrical and computer engineering and a Master of Science degree in physics from Northwestern University, as well as a bachelor’s degree from the Indian Institute of Technology in Bombay.

Darren brings over 25 years of experience in developing, executing, and investing in growth strategies for emerging technology companies. Prior to joining Dreamit, Darren was a Board Member and held various operating positions at CIML LLC, a holding company for Channel Intelligence (acquired by Google). Darren also spent over 10 years as a private equity and venture investor at Actua, an investment and holding company for SaaS-based technology companies, where he served as a Managing Director. In the capacity of Managing Director, Darren was responsible for sourcing potential investment opportunities and leading the acquisition of portfolio companies, including business model diligence, transaction structuring and post- acquisition growth acceleration. Prior to Actua, Darren held various financial and operating positions. Darren started his career at Andersen in their enterprise division. Darren’s passion and unique strength is identifying promising companies, technologies and people, and helping them develop strategies to achieve their vision.